A Phase 1/2 interventional study of ATR04-484 and Vehicle in EGFR Inhibitor-associated Rash, sponsored by Azitra Inc.. Recruiting at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by Azitra Inc. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Exanthema with a site in United States — 4 open to participants now, 4 under way, 1 of them phase 3. Exanthema · United States.
Among the 24 studies in Exanthema with a site in United States, this one is the 5th largest by planned enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2025, is one of 2 in phase 1/2, and was the 22nd registered.
68 studies on the registry are indexed under Exanthema; 11 are open to participants now.
Browse Exanthema studies →4 of the 24 studies in Exanthema with a site in United States are open now. Recruiting first, the newest first:
Maryam Lustberg · Sites in United States
Ages 18+ · Healthy volunteers
Bristol-Myers Squibb · Sites in United States, Argentina, Belgium and 13 more countries
Ages 12–17
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 2–100
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 8 Exanthema studies recruiting now, 3 set no upper age limit and 3 stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 11 · Phase 3 2 · Phase 4 3
First in 2002; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 32 is below the median of 60 across 45 interventional studies indexed under Exanthema.
Median enrollment 14 across the 18 interventional studies, 25 across the 6 observational. Of the 18 that completed or were terminated, 11 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 24 have an industry lead sponsor. The 10 most frequent:
Azitra Inc. is the lead sponsor of 4 studies on the registry; 1 is open to participants now.
Azitra Inc. has 1 study filed under Exanthema — fewer than ten, so there is no comparison to draw.
3 of the studies in Exanthema with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06096857National Institute of Allergy and Infectious Diseases (NIAID)Cardamom and Topical Roseomonas in Atopic Dermatitis | 2027-01-01 |
| NCT07426822Maryam LustbergRash & Diarrhea Prophylaxis With Capivasertib | 2027-04 |
| NCT06830863Azitra Inc.A Study to Evaluate Topical ATR04-484 for EGFRi-Associated Dermal Toxicity | 2027-07-15 |
Add all 3 to your calendar (.ics) → With an account.
Among the 24 studies in Exanthema with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this randomized clinical trial is to learn if topical treatment with ATR04-484 can treat skin rash in patients undergoing EGFR inhibitor (EGFRi) therapy. The primary goal of the study is to determine safety and tolerability of ATR04-484, and the secondary goal of the study is to assess efficacy signals of ATR04-484. Researchers will compare treatment of ATR04-484 to its vehicle. Participants will:
This is a multicenter, randomized, blinded, vehicle-controlled Phase 1/2 trial of topically applied ATR04-484 in adult patients with moderate to severe EGFRi-related non-infected dermal toxicity affecting the face. The neck, chest, back, and other areas may also be affected.
The safety, bioavailability, pharmacodynamics (PD), and preliminary effect of ATR04-484 (at a single concentration) will be compared to that of its vehicle, in 2 patient cohorts. In each cohort, eligible patients will be randomized (3:1 ratio) to ATR04-484 or its vehicle. The initial cohort (n = 8) will receive a single 4 g application of the study drug to the face, chest, and back, followed by a 7-day observation period. Upon completion of this observation period, the patients in this cohort may continue in the study with daily applications of study drug for an additional 28 days. Following a safety observation period, a subsequent cohort (n = 24) may be enrolled and will receive a 4 g application of the study drug once daily for 28 days. Each cohort will be followed for 28 days after the last application of study drug.
Clinical assessments of treatment effect will be evaluated at each area that has received a full application of study drug (coverage of all lesional surfaces). The primary endpoint is safety and tolerability. Secondary endpoints including clinical efficacy, including: (1) the severity of the dermal toxicity using a 5-point regional assessment scale, based on modified CTCAE descriptors for skin toxicity (including a score of 0 for clear or unaffected skin through 4 for severely affected skin); (2) numeric rating scales for pruritus and pain; and (3) a quality-of-life assessment (Functional Assessment of Cancer Therapy-EGFRI 18 [FACT-EGFRI 18]). Bioavailability of ATR04-484 will also be assessed.
The criteria were revised on the registry on Oct 13, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Topically applied ATR04-484
Drug: ATR04-484
Topically applied vehicle
Drug: Vehicle
ATR04-484 is a recombinant live biotherapeutic product (rLBP) containing the engineered S. epidermidis strain SE484 in an ointment formulation for topical use
Also known as: ATR-04
Topically applied vehicle.
Safety and tolerability
Treatment-emergent adverse events
Time frame: 57 days
Severity of dermal toxicity
Investigator assessment of dermal toxicity using a 5-point regional assessment scale, based on modified CTCAE descriptors for skin toxicity (including a score of 0 for clear or unaffected skin through 4 for severely affected skin).
Time frame: 57 days
Pruritus
Patient reported via numeric rating scale for reflective (24 hour) pruritus
Time frame: 57 days
Quality-of-life assessment
Patient reported using Functional Assessment of Cancer Therapy-EGFRI 18 \[FACT-EGFRI 18\]
Time frame: 57 days
Bioavailability of ATR04-484
The bioavailability of SE484 will be assessed by qPCR
Time frame: 57 days
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2025 (actual). Primary completion is estimated for Jul 2027, 22 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: primary completion Jan 2027 → Jul 2027 and completion Feb 2027 → Sep 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.